2 results
Approved WMORecruiting
To compare the progression free survival and neurotoxity of first line treatment with F-Nal-IRI, CapCar and CapOx.
Approved WMORecruiting
The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.